TPST insider trading
NasdaqCM HealthcareTempest Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Company website: www.tempesttx.com
TPST insider activity at a glance
FilingIQ has scored 28 insider transactions for TPST since Jun 25, 2021. The most recent filing in our index is dated Jun 4, 2026.
Across the full history, 10 open-market purchases
and 2 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on TPST insider trades is 68.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest TPST Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading TPST
Frequently asked
- How many insider trades does FilingIQ track for TPST?
- FilingIQ tracks 28 Form 4 insider transactions for TPST (Tempest Therapeutics, Inc.), covering filings from Jun 25, 2021 onwards. 4 of those were filed in the last 90 days.
- Are TPST insiders net buyers or net sellers?
- Across the full Form 4 history for TPST, 10 transactions (36%) were open-market purchases and 2 (7%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does TPST insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is TPST in?
- Tempest Therapeutics, Inc. (TPST) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $23.09M.
Methodology & sources
Every TPST insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.